Guardant Health, Inc. (NASDAQ:GH - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $32.00 to $28.00. The Goldman Sachs Group currently has a buy rating on the stock. Guardant Health traded as low as $16.28 and last traded at $16.36, with a volume of 170032 shares trading hands. The stock had previously closed at $17.06.
Several other analysts have also recently issued reports on the company. Piper Sandler decreased their price objective on Guardant Health from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Monday, February 26th. Canaccord Genuity Group decreased their price objective on Guardant Health from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Friday, February 23rd. JPMorgan Chase & Co. decreased their price objective on Guardant Health from $60.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, February 23rd. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Guardant Health in a report on Friday, April 5th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Guardant Health presently has an average rating of "Moderate Buy" and an average price target of $40.40.
Check Out Our Latest Research Report on GH
Insider Transactions at Guardant Health
In other news, insider Kumud Kalia purchased 2,187 shares of the company's stock in a transaction dated Monday, March 18th. The shares were acquired at an average price of $17.82 per share, with a total value of $38,972.34. Following the transaction, the insider now owns 12,722 shares of the company's stock, valued at $226,706.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 6.20% of the company's stock.
Institutional Investors Weigh In On Guardant Health
Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC boosted its position in Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company's stock valued at $29,000 after purchasing an additional 569 shares in the last quarter. BluePath Capital Management LLC bought a new stake in Guardant Health during the third quarter valued at about $35,000. Acadian Asset Management LLC bought a new stake in Guardant Health during the first quarter valued at about $37,000. Captrust Financial Advisors boosted its holdings in Guardant Health by 33.2% in the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company's stock worth $44,000 after acquiring an additional 271 shares in the last quarter. Finally, Headlands Technologies LLC boosted its holdings in Guardant Health by 362.3% in the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company's stock worth $64,000 after acquiring an additional 1,844 shares in the last quarter. Institutional investors own 92.60% of the company's stock.
Guardant Health Stock Performance
The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -3.78 and a beta of 0.87. The firm has a fifty day simple moving average of $19.57 and a two-hundred day simple moving average of $23.45.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The business had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. On average, analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current year.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Stories
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
